Hospital
Mymichigan Medical Center Saginaw
Mymichigan Medical Center Saginaw was paid $38.70M by Medicaid between Jan 2018 and Dec 2024, across 340 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.
33Billing provider infoMYMICHIGAN MEDICAL CENTER SAGINAW
SAGINAW, MI 48601
SAGINAW, MI 48601
33aNPI1871507509assigned 07/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.70M
24GClaims1,296,501
24DCodes billed340
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#33 of 86
Median peer was paid$21.55M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JAMES, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 195,327 | $5.66M | |
| 2019 | 200,552 | $5.40M | |
| 2020 | 162,267 | $4.34M | |
| 2021 | 189,463 | $5.97M | |
| 2022 | 207,601 | $6.21M | |
| 2023 | 199,085 | $6.08M | |
| 2024incomplete | 142,206 | $5.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 21,807 | 20,285 | $7.12M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 40,014 | 37,348 | $6.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 42,718 | 40,743 | $5.11M |
| H2015 | Community support for mental illness or disability, per 15 minutesComprehensive community support services, per 15 minutes | 11% | 72,436 | 4,226 | $4.22M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.6% | 25,858 | 23,390 | $2.16M |
| T1005 | Respite care services, up to 15 minutes | 3.7% | 67,938 | 2,318 | $1.43M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 5,617 | 5,438 | $719K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 3,267 | 3,232 | $558K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.4% | 18,360 | 4,903 | $556K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 25,962 | 6,580 | $549K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 16,275 | 14,059 | $528K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 19,337 | 16,218 | $486K |
328 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 6,399 | $440K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 13,235 | $439K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 2,619 | $424K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 5,733 | $423K |
| G0378 | Hospital observation service, per hour | 1.1% | 5,484 | $421K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 998 | $368K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,841 | $328K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 9,484 | $321K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,283 | $286K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,773 | $257K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,802 | $254K |
| 80061 | Lipid panel | <1% | 7,848 | $241K |
| 94060 | <1% | 1,774 | $216K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,233 | $188K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,141 | $169K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,758 | $159K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,935 | $153K |
| 97163 | <1% | 2,760 | $148K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,393 | $138K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,392 | $131K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,369 | $124K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,592 | $119K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 596 | $113K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,394 | $107K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,455 | $105K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,580 | $105K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 221 | $99K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 170 | $88K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 151 | $83K |
| 95911 | <1% | 374 | $83K | |
| 93971 | <1% | 1,712 | $79K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,029 | $65K |
| 76830 | Ultrasound, transvaginal | <1% | 1,161 | $64K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 571 | $64K |
| 72131 | <1% | 1,866 | $61K | |
| 80053 | Comprehensive metabolic panel | <1% | 49,135 | $55K |
| 93017 | <1% | 1,988 | $53K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,809 | $53K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,767 | $52K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 643 | $51K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 987 | $49K |
| 72141 | <1% | 450 | $49K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,594 | $40K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,804 | $39K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,648 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,086 | $37K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,117 | $33K |
| 76881 | <1% | 583 | $32K | |
| 73564 | <1% | 2,526 | $31K | |
| 72110 | <1% | 1,141 | $29K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,584 | $26K |
| 70496 | <1% | 282 | $26K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,158 | $25K |
| 72100 | <1% | 1,269 | $25K | |
| 95910 | <1% | 201 | $24K | |
| 74018 | <1% | 2,424 | $24K | |
| 76000 | <1% | 590 | $23K | |
| 95909 | <1% | 171 | $22K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,841 | $21K |
| 76642 | <1% | 516 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,310 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,515 | $19K |
| 95806 | <1% | 230 | $18K | |
| 10060 | <1% | 254 | $18K | |
| 76536 | <1% | 379 | $18K | |
| 73030 | <1% | 2,520 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,066 | $17K |
| 73630 | <1% | 2,828 | $17K | |
| 97167 | <1% | 388 | $17K | |
| 73130 | <1% | 2,558 | $16K | |
| 93458 | <1% | 19 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,234 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,729 | $15K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 45 | $15K |
| 93351 | <1% | 88 | $15K | |
| 93225 | <1% | 382 | $14K | |
| 95819 | <1% | 134 | $14K | |
| 71271 | <1% | 276 | $13K | |
| 71250 | <1% | 245 | $12K | |
| 86900 | <1% | 3,634 | $12K | |
| 97162 | <1% | 285 | $12K | |
| 99406 | <1% | 1,184 | $11K | |
| 76775 | <1% | 432 | $11K | |
| 82607 | <1% | 2,294 | $10K | |
| 88304 | <1% | 1,325 | $10K | |
| 97161 | <1% | 252 | $10K | |
| 86780 | <1% | 212 | $9K | |
| 97116 | <1% | 1,227 | $9K | |
| 84439 | <1% | 6,303 | $9K | |
| 73610 | <1% | 2,386 | $9K | |
| 70486 | <1% | 433 | $8K | |
| 82728 | <1% | 1,490 | $7K | |
| 97803 | <1% | 993 | $6K | |
| 96367 | <1% | 278 | $6K | |
| 82746 | <1% | 1,453 | $6K | |
| 93970 | <1% | 76 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,977 | $6K |
| 73502 | <1% | 979 | $6K | |
| 72050 | <1% | 142 | $6K | |
| 73110 | <1% | 1,336 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 102 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 417 | $5K |
| 88342 | <1% | 244 | $5K | |
| 93226 | <1% | 494 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 53 | $5K |
| 29540 | <1% | 91 | $5K | |
| 83970 | <1% | 275 | $5K | |
| 83550 | <1% | 1,413 | $5K | |
| 93880 | <1% | 59 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,285 | $4K |
| 95811 | <1% | 12 | $4K | |
| 73221 | <1% | 37 | $4K | |
| 72128 | <1% | 310 | $4K | |
| 94726 | <1% | 1,738 | $4K | |
| 74022 | <1% | 4,242 | $4K | |
| 76801 | <1% | 78 | $4K | |
| 83735 | <1% | 19,291 | $4K | |
| 83540 | <1% | 1,550 | $4K | |
| 86140 | <1% | 9,757 | $4K | |
| 85610 | <1% | 11,986 | $3K | |
| 97597 | <1% | 42 | $3K | |
| 88307 | <1% | 70 | $3K | |
| 96415 | <1% | 68 | $3K | |
| 97602 | <1% | 34 | $3K | |
| 83880 | <1% | 3,277 | $3K | |
| 80306 | <1% | 5,899 | $2K | |
| 86850 | <1% | 3,167 | $2K | |
| 87070 | <1% | 3,136 | $2K | |
| 29515 | <1% | 32 | $2K | |
| 87077 | <1% | 1,316 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 45 | $2K |
| 85027 | <1% | 1,793 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,517 | $2K |
| 82043 | <1% | 715 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,754 | $1K |
| 73080 | <1% | 392 | $1K | |
| 87186 | <1% | 2,944 | $1K | |
| 84702 | <1% | 1,580 | $1K | |
| 84153 | <1% | 194 | $1K | |
| 72040 | <1% | 45 | $1K | |
| 82550 | <1% | 10,845 | $1K | |
| 64400 | <1% | 13 | $1K | |
| 85652 | <1% | 3,547 | $1K | |
| 73590 | <1% | 423 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 106 | $1K |
| 83690 | <1% | 17,881 | $1K | |
| 83013 | <1% | 40 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,972 | $1K |
| 72170 | <1% | 910 | $1K | |
| 70498 | <1% | 307 | $1K | |
| 84100 | <1% | 6,525 | $1K | |
| 86480 | <1% | 55 | $1K | |
| 74019 | <1% | 165 | $1K | |
| 94618 | <1% | 189 | $1K | |
| 85730 | <1% | 8,367 | $1K | |
| 81003 | <1% | 22,790 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 115 | $1K |
| 87420 | <1% | 636 | $1K | |
| 80076 | <1% | 783 | $1K | |
| 97760 | <1% | 29 | $986.20 | |
| 82570 | <1% | 496 | $954.75 | |
| 87205 | <1% | 1,528 | $951.40 | |
| 73140 | <1% | 328 | $934.55 | |
| 86039 | <1% | 231 | $933.36 | |
| 87088 | <1% | 2,592 | $930.11 | |
| 86901 | <1% | 3,628 | $929.00 | |
| 73700 | <1% | 16 | $910.70 | |
| 93308 | <1% | 12 | $844.94 | |
| 85007 | <1% | 1,688 | $837.66 | |
| 84703 | <1% | 6,747 | $814.47 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 33 | $808.36 |
| 73562 | <1% | 165 | $777.51 | |
| 81001 | <1% | 8,611 | $771.24 | |
| 80074 | <1% | 38 | $753.69 | |
| 72072 | <1% | 38 | $739.14 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 49 | $728.97 |
| 84484 | <1% | 15,726 | $716.77 | |
| 76870 | <1% | 40 | $709.92 | |
| 81025 | <1% | 15,889 | $680.52 | |
| 82962 | <1% | 8,619 | $654.89 | |
| 86038 | <1% | 168 | $652.90 | |
| 76882 | <1% | 17 | $623.45 | |
| 82565 | <1% | 362 | $620.52 | |
| 86235 | <1% | 61 | $612.19 | |
| 87631 | <1% | 501 | $571.16 | |
| 82553 | <1% | 4,356 | $566.73 | |
| 83516 | <1% | 109 | $534.74 | |
| 83605 | <1% | 13,273 | $525.09 | |
| 73090 | <1% | 312 | $392.37 | |
| 84436 | <1% | 138 | $391.60 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,257 | $383.03 |
| 82330 | <1% | 827 | $381.03 | |
| 82150 | <1% | 1,404 | $355.52 | |
| 73560 | <1% | 153 | $338.76 | |
| 73120 | <1% | 23 | $338.58 | |
| 84460 | <1% | 204 | $323.45 | |
| 83615 | <1% | 408 | $319.89 | |
| 84450 | <1% | 203 | $314.88 | |
| 84425 | <1% | 53 | $311.49 | |
| 86803 | <1% | 51 | $311.01 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,754 | $297.22 |
| 85379 | <1% | 3,132 | $287.82 | |
| 87040 | <1% | 2,170 | $260.10 | |
| 86431 | <1% | 139 | $253.10 | |
| 84520 | <1% | 168 | $241.14 | |
| 87634 | <1% | 1,323 | $203.57 | |
| 71101 | <1% | 13 | $195.15 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 190 | $190.46 |
| 84550 | <1% | 153 | $187.44 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 334 | $168.74 |
| 86200 | <1% | 40 | $162.32 | |
| 84146 | <1% | 61 | $156.76 | |
| 87210 | <1% | 4,376 | $149.54 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 24 | $114.46 |
| 97804 | <1% | 28 | $112.00 | |
| 82274 | <1% | 103 | $110.72 | |
| 86160 | <1% | 25 | $99.85 | |
| 87340 | <1% | 24 | $97.13 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,343 | $96.17 |
| A9270 | Non-covered item or service | <1% | 46,137 | $91.66 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26,771 | $88.17 |
| 99407 | <1% | 13 | $67.68 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 19 | $66.47 |
| 93320 | <1% | 148 | $66.11 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,588 | $60.00 |
| 82800 | <1% | 794 | $57.79 | |
| 29125 | <1% | 61 | $54.30 | |
| 86308 | <1% | 334 | $53.21 | |
| 93325 | <1% | 149 | $49.13 | |
| 73600 | <1% | 16 | $48.33 | |
| 73620 | <1% | 36 | $48.33 | |
| 86256 | <1% | 12 | $46.01 | |
| 84132 | <1% | 54 | $45.87 | |
| 82378 | <1% | 14 | $45.74 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 18 | $39.60 |
| 87481 | <1% | 18 | $39.60 | |
| 84480 | <1% | 13 | $30.46 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,805 | $25.79 |
| 85018 | <1% | 174 | $24.97 | |
| 85014 | <1% | 188 | $24.97 | |
| 82010 | <1% | 876 | $19.26 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,971 | $18.00 |
| 85044 | <1% | 13 | $15.35 | |
| 82248 | <1% | 15 | $12.30 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,042 | $10.20 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,509 | $9.73 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,624 | $8.93 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 58 | $1.04 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 13 | $0.29 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 66 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 2,281 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 3,071 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,830 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 4,539 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 6,186 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,090 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 436 | $0.00 |
| 96376 | 0% | 6,788 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 13 | $0.00 |
| 97010 | 0% | 5,238 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 777 | $0.00 |
| 95886 | 0% | 2,313 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,218 | $0.00 |
| 94200 | 0% | 90 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 6,692 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,979 | $0.00 |
| C1769 | Guide wire | 0% | 1,639 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 881 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 824 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 5,384 | $0.00 |
| 94760 | 0% | 1,376 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 113 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 318 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 99 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 320 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 163 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 351 | $0.00 |
| J3490 | Unclassified drugs | 0% | 2,118 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 163 | $0.00 |
| 12001 | 0% | 192 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 339 | $0.00 |
| 81015 | 0% | 77 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 281 | $0.00 |
| 82803 | 0% | 25 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 12 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 67 | $0.00 |
| 0399T | 0% | 13 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 53 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 17 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 27 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 88 | $0.00 |
| 12002 | 0% | 40 | $0.00 | |
| 76377 | 0% | 12 | $0.00 | |
| 96368 | 0% | 15 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 31 | $0.00 |
| 29130 | 0% | 14 | $0.00 | |
| 84145 | 0% | 307 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 3,884 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 555 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 5,443 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 1,783 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 3,856 | $0.00 |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 347 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,231 | $0.00 |
| 94729 | 0% | 1,839 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 41 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 252 | $0.00 |
| 93356 | 0% | 1,169 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 671 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 2,688 | $0.00 |
| 90715 | 0% | 1,703 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 917 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,266 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 131 | $0.00 |
| 29530 | 0% | 77 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 535 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 169 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 27 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 161 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 174 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 106 | $0.00 |
| 29260 | 0% | 35 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 20 | $0.00 |
| 85384 | 0% | 25 | $0.00 | |
| 12011 | 0% | 14 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 71 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 21 | $0.00 |
| 84207 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMES, SARAH (MANAGER PATIENT ACCOUNTING)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.